Year to 31 March 2019 AGM, November 2019 1 Financial summary: - - PowerPoint PPT Presentation

1

Annual Results Year to 31 March 2019

AGM, November 2019

2

Financial summary: underlying performance to 31 March 2019

0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0%

• 1,000

1,000 2,000 3,000 4,000 5,000 6,000 2015 2016 2017 2018 2019 2019

Trading Income One-offs EBITDA One-offs as % of total revenue

£000

Actual

7m of Medimark

Run rate

12m of Medimark

Byotrol plc estimates: smoothed net income from Solvay deal 2018/1019, non-recurring costs included as costs

3

Byotrol plc: Technologies

Traditional Technologies Newly Developed Technologies

HLD4 BYOTROL 24 HAND SANITISER HOCL ACTIZONE*

Surface care for EU BPR and MDD Surface care for US EPA Surface care for EU BPR Sporicidal surface care for EU BPR and MDD Alcohol-free hand sanitisers for EU under BPR

HEALTHCARE OTHER PROF. CONSUMER

Animal Healthcare Human Healthcare Food Jansan Retail Incl petcare

Technology Platforms Market Segments BPR - Biocides Products Regulation (EU) MDD – Medical Device Directive (EU) EPA – Environmental Protection Agency (US) Relevant Regulatory Agency

Seaweed – anti virals Surface care & QFS

* In alliance with Solvay

4

Byotrol plc: US surface care

• US EPA-approved, long-lasting germ kill surface cleaner/sanitiser. Unique claims for US consumer
• market. US$1bn addressable market.
• Target ‘trial’ in 207 stores across US remains underway; no discrete end date, but progress is under

regular review… and sales increasing despite minimal marketing spend

• Extensive consumer research now completed by Nielsen. Confirms strength of proposition:
• 79% Agree – A 24-hour surface sanitizer is a good idea and I would use it in my home.
• 78% Agree – I trust Byotrol24 would keep my surfaces sanitized for 24 hours.
• 64% Agree – I think Byotrol24 would work better than the current all-purpose cleaner I use.
• Now seeking financial or corporate partner to accelerate growth.

$ $500 $1,000 $1,500 $2,000

Sales $'s TY vs. LY

This Year 2019 Last Year2018

5

Byotrol plc: outlook

• Progressing with plan
• Technology-led sales in Professional markets – especially animal health, human health -

and in Consumer

• EU Surface care via Medimark products and Solvay(Actizone)
• US surface care: product proposition established; now seeking partner to accelerate growth
• Expansion of alcohol-free hand sanitisers launched into healthcare – direct and white label
• Integrating Medimark
• Strategic planning mode at present – identifying synergies including: costs, rationalising

technologies, monetisation strategies for non core technologies

• Execution post completion of earnout on 31 March 2020
• Still very well-positioned for long-term growth
• Visible, sustainable profits in sight from trading income only
• Monetisation opportunities for legacy technologies and new technologies
• Strong balance sheet
• Strong leadership team
• Positive market dynamics – growing market, regulations biting, consolidation underway